AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15051595 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise
Number of subjects: 316
Study 12365866 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 80
Study 12365866 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 80
Study 8981380 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous trial with incorrect response
Number of subjects: 0
Study 8981380 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous LVF target (word)
Number of subjects: 0
Study 8981380 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous LVF target (nonword)
Number of subjects: 0
Study 8981380 — intervention group
Group type: COMPARATOR
Intervention: Same response category as unattended stimulus in previous trial
Number of subjects: 0
Study 7653742 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg
Number of subjects: 42
Study 7653742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 3602020 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg naproxen twice daily
Number of subjects: 60
Study 3602020 — intervention group
Group type: COMPARATOR
Intervention: 400 mg pirprofen twice daily
Number of subjects: 60
Study 31576959 — intervention group
Group type: EXPERIMENTAL
Intervention: NSD plus MTZ (400 mg) and AMX (500 mg) three times a day for 14 days
Number of subjects: 40
Study 31576959 — intervention group
Group type: COMPARATOR
Intervention: NSD plus placebo
Number of subjects: 40
Study 29921143 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantram repetition therapy
Number of subjects: 173
Study 29921143 — intervention group
Group type: COMPARATOR
Intervention: Present-centered therapy
Number of subjects: 173
Study 27730819 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium nitrate treatment
Number of subjects: 0
Study 27730819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24478129 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil/Lymphocyte Ratio (NLR) in patients with HP infection
Number of subjects: 50
Study 24478129 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil/Lymphocyte Ratio (NLR) in symptomatic HP patients with grade 4 gastritis
Number of subjects: 50
Study 24478129 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil/Lymphocyte Ratio (NLR) as severity of gastritis increases
Number of subjects: 50
Study 24478129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off level for NLR
Number of subjects: 50
Study 23147874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Volume Loop (PV-L) closure technique
Number of subjects: 140
Study 23147874 — intervention group
Group type: COMPARATOR
Intervention: Fixed preset pressure technique
Number of subjects: 140
Study 23147874 — intervention group
Group type: COMPARATOR
Intervention: Pilot balloon palpation technique
Number of subjects: 140
Study 18084052 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed format
Number of subjects: 575
Study 18084052 — intervention group
Group type: EXPERIMENTAL
Intervention: Group format
Number of subjects: 575
Study 17975151 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-peptide vaccine containing a mixture of 12 peptides from melanocytic differentiation proteins and cancer‐testis antigens
Number of subjects: 0
Study 17975151 — intervention group
Group type: COMPARATOR
Intervention: 4-peptide vaccine with only melanocytic differentiation peptides
Number of subjects: 0
Study 14727004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.4 mg kg(‐1))
Number of subjects: 54
Study 14727004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.8 mg kg(‐1))
Number of subjects: 54
Study 14727004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11808908 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA patch
Number of subjects: 161
Study 11808908 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 161
Study 9748796 — intervention group
Group type: EXPERIMENTAL
Intervention: AC (doxorubicin, cyclophosphamide)
Number of subjects: 106
Study 9748796 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 106
Study 8153291 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) 1-1.38 mg/kg/day for 21 days
Number of subjects: 31
Study 8153291 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) 3 mg/kg/day for 10 days
Number of subjects: 31
Study 8153291 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) 100 mg (1.38-1.85 mg/kg) daily for 21 days
Number of subjects: 31
Study 3046404 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline delivered by a nebuhaler
Number of subjects: 15
Study 3046404 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline delivered by a tube spacer
Number of subjects: 15
Study 3046404 — intervention group
Group type: COMPARATOR
Intervention: pressurized aerosol
Number of subjects: 15
Study 29118060 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNFR-1/2
Number of subjects: 0
Study 29118060 — intervention group
Group type: EXPERIMENTAL
Intervention: sE-selectin
Number of subjects: 0
Study 29118060 — intervention group
Group type: EXPERIMENTAL
Intervention: fibrinogen
Number of subjects: 0
Study 29118060 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-1
Number of subjects: 0
Study 29118060 — intervention group
Group type: EXPERIMENTAL
Intervention: biomarkers (sTNFR-1/2, sE-selectin, PAI-1, and fibrinogen)
Number of subjects: 0
Study 26817735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7007
Study 26817735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7007
Study 26324220 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 666
Study 26324220 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 666
Study 26324220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 666
Study 24156925 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally responsive health promotion program (CHP-K) consisting of 8 weeks of Qi exercise and face-to-face counseling on physical and psychological factors.
Number of subjects: 63
Study 24156925 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail in the abstract).
Number of subjects: 63
Study 21843837 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles (5 degrees) made of high density ethyl vinyl acetate, worn bilaterally every day for 12 months.
Number of subjects: 200
Study 21843837 — intervention group
Group type: COMPARATOR
Intervention: Flat control insoles made of low density ethyl vinyl acetate, worn bilaterally every day for 12 months.
Number of subjects: 200
Study 21843837 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles (5 degrees)
Number of subjects: 200
Study 21843837 — intervention group
Group type: COMPARATOR
Intervention: Flat control insoles
Number of subjects: 200
Study 18355744 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (didactic session and posting criteria for asthma severity classification)
Number of subjects: 12
Study 18355744 — intervention group
Group type: COMPARATOR
Intervention: Control group (data from 2002-2003)
Number of subjects: 12
Study 16977645 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver skill training intervention
Number of subjects: 131
Study 12639652 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic injection of 10 mL of 2% lidocaine solution without epinephrine
Number of subjects: 100
Study 12639652 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 mL of 0.9% NaCl)
Number of subjects: 100
Study 11189013 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin for up to 4 weeks
Number of subjects: 20000
Study 11189013 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (intravenous then oral) for up to 4 weeks
Number of subjects: 20000
Study 11189013 — intervention group
Group type: COMPARATOR
Intervention: Placebo for up to 4 weeks
Number of subjects: 20000
Study 9202354 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricle to axillary patch configuration (12.7 +/- 5.9 J)
Number of subjects: 16
Study 9202354 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricle to superior vena cava plus axillary patch configuration (9.8 +/- 5.2 J)
Number of subjects: 16
Study 9202354 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricle to pectoral can configuration (9.2 +/- 5.1 J)
Number of subjects: 16
Study 9202354 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricle to array configuration (5.6 +/- 3.6 J)
Number of subjects: 16
Study 9202354 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy endocardial defibrillation (< or =10 J)
Number of subjects: 16
Study 9202354 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy endocardial defibrillation (5 J)
Number of subjects: 16
Study 8246533 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator and fibrin monomers
Number of subjects: 0
Study 8246533 — intervention group
Group type: EXPERIMENTAL
Intervention: Retransfusion of shed blood
Number of subjects: 0
Study 8246533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen degradation products and tissue-type plasminogen activator stimulating activity
Number of subjects: 0
Study 3963028 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (200 mg per day)
Number of subjects: 822
Study 3963028 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (4,000 mg per day)
Number of subjects: 822
Study 3963028 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 822
Study 3963028 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 822
Study 30917364 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy with intensive SBP goal < 120 mm Hg
Number of subjects: 2646
Study 30917364 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy with standard SBP goal < 140 mm Hg
Number of subjects: 2646
Study 30917364 — intervention group
Group type: COMPARATOR
Intervention: Non-statin therapy with intensive SBP goal < 120 mm Hg
Number of subjects: 2646
Study 30917364 — intervention group
Group type: COMPARATOR
Intervention: Non-statin therapy with standard SBP goal < 140 mm Hg
Number of subjects: 2646
Study 29277378 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 0
Study 29277378 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 0
Study 27530088 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid
Number of subjects: 0
Study 27530088 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 0
Study 24433061 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg/day) for 12 weeks
Number of subjects: 18
Study 24433061 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II receptor antagonists (ARBs)
Number of subjects: 18
Study 22538670 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal repair (TAPP)
Number of subjects: 185
Study 22538670 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 185
Study 20541347 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based AAA screening
Number of subjects: 4
Study 17113685 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins (2mg of folate, 25mg of B6, 400 microg of B12)
Number of subjects: 299
Study 17113685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 16154305 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (5.1g b.i.d.)
Number of subjects: 49
Study 16154305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 11873030 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 24
Study 11873030 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 24
Study 10468987 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy (0.036 U/kg/d)
Number of subjects: 18
Study 10468987 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 18
Study 7595856 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy at the anaerobic threshold (AT) level continued after discharge (group T)
Number of subjects: 62
Study 7595856 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C) with exercise therapy discontinued after discharge
Number of subjects: 62
Study 7595856 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (T and C)
Number of subjects: 62
Study 2112480 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g glucose and 120 g milk fat with 10 microCi U‐14C oleic acid given in the overnight fasting state
Number of subjects: 16
Study 2112480 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g glucose and 120 g milk fat with 10 microCi U‐14C oleic acid given 2 h after a carbohydrate-rich meal
Number of subjects: 16
Study 521570 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 0
Study 521570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31092670 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Help Plus (SH+)
Number of subjects: 1200
Study 31092670 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual
Number of subjects: 1200
Study 28426857 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-made spectacles (n=232)
Number of subjects: 460
Study 28426857 — intervention group
Group type: COMPARATOR
Intervention: Custom-made spectacles (n=228)
Number of subjects: 460
Study 25565796 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium 125 μg
Number of subjects: 18
Study 25565796 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol 125/25 μg
Number of subjects: 18
Study 24288513 — intervention group
Group type: COMPARATOR
Intervention: 0 ppm nanocide in drinking water
Number of subjects: 270
Study 24288513 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ppm nanocide in drinking water
Number of subjects: 270
Study 24288513 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ppm nanocide in drinking water
Number of subjects: 270
Study 24288513 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ppm nanocide in drinking water
Number of subjects: 270
Study 24288513 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ppm nanocide in drinking water
Number of subjects: 270
Study 24288513 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 ppm nanocide in drinking water
Number of subjects: 270
Study 21737469 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 892
Study 21737469 — intervention group
Group type: COMPARATOR
Intervention: Self monitoring of blood glucose
Number of subjects: 892
Study 19214042 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived carer criticism
Number of subjects: 67
Study 19214042 — intervention group
Group type: EXPERIMENTAL
Intervention: High expressed emotion (EE)
Number of subjects: 67
Study 17537292 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 2452
Study 17537292 — intervention group
Group type: COMPARATOR
Intervention: No iron supplementation
Number of subjects: 2452
Study 15848529 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of MMF or AZA to 75% and then to 50% of the original dose at 4 months and 8 months after inclusion.
Number of subjects: 45
Study 11205419 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate MDMA use
Number of subjects: 62
Study 11205419 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy MDMA use
Number of subjects: 62
Study 11205419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecstasy users (both moderate and heavy)
Number of subjects: 62
Study 11205419 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MDMA use)
Number of subjects: 62
Study 9024731 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) with nitroglycerin (NTG) infusion
Number of subjects: 16
Study 9024731 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (NTG) infusion alone
Number of subjects: 16
Study 8335968 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1-derived recombinant live vaccina-gp160
Number of subjects: 4
Study 8335968 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified rgp160 (boost)
Number of subjects: 4
Study 8335968 — intervention group
Group type: COMPARATOR
Intervention: CD8+ cell depletion
Number of subjects: 4
Study 8335968 — intervention group
Group type: COMPARATOR
Intervention: HLA class I-mismatched target cells
Number of subjects: 4
Study 3523041 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperatively administered plasma proteins
Number of subjects: 94
Study 3523041 — intervention group
Group type: COMPARATOR
Intervention: Control group (no plasma proteins)
Number of subjects: 94
Study 2471718 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 434 (5 mg loratadine and 120 mg pseudoephedrine, administered twice daily)
Number of subjects: 435
Study 2471718 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine alone (component of SCH 434)
Number of subjects: 435
Study 2471718 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine alone (component of SCH 434)
Number of subjects: 435
Study 2471718 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 434
Number of subjects: 435
Study 2471718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study 31222628 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat percentage
Number of subjects: 18542
Study 31222628 — intervention group
Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 18542
Study 28970080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacc-4x
Number of subjects: 104
Study 28970080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 26995988 — intervention group
Group type: EXPERIMENTAL
Intervention: Early chemoradiotherapy (CRT) without induction chemotherapy (IC) by capecitabine
Number of subjects: 3
Study 26995988 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed CRT with 4 or 8 courses of IC by capecitabine
Number of subjects: 3
Study 26995988 — intervention group
Group type: COMPARATOR
Intervention: Whole brain radiation therapy (historical control)
Number of subjects: 3
Study 26995988 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 3
Study 24132975 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl-d9-choline (22% of total choline intake, 480 or 930 mg/d)
Number of subjects: 47
Study 20843868 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy
Number of subjects: 94
Study 19745163 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine stimulation
Number of subjects: 0
Study 19745163 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of Sp1 and AP-1 activations by specific siRNA
Number of subjects: 0
Study 19745163 — intervention group
Group type: COMPARATOR
Intervention: Preshearing of ECs for 1 to 4 hours at 20 dyn/cm2
Number of subjects: 0
Study 19745163 — intervention group
Group type: COMPARATOR
Intervention: NO donor
Number of subjects: 0
Study 19745163 — intervention group
Group type: COMPARATOR
Intervention: Inhibitor or siRNA for endothelial NO synthase
Number of subjects: 0
Study 16283367 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT+ (hormone replacement therapy)
Number of subjects: 45
Study 16283367 — intervention group
Group type: COMPARATOR
Intervention: HRT- (no hormone replacement therapy)
Number of subjects: 45
Study 16283367 — intervention group
Group type: COMPARATOR
Intervention: Young subjects
Number of subjects: 45
Study 16283367 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT+
Number of subjects: 45
Study 16283367 — intervention group
Group type: COMPARATOR
Intervention: HRT-
Number of subjects: 45
Study 16283367 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (HRT+, HRT-, Young)
Number of subjects: 45
Study 15332999 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to radiation from the Chernobyl Power Station accident
Number of subjects: 78
Study 15332999 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched by gender, birth year, and raion of residence)
Number of subjects: 78
Study 10647724 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK with Chiron Hansatome microkeratome and Summit Apex Plus excimer laser
Number of subjects: 63
Study 9077616 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2% solution
Number of subjects: 1024
Study 9077616 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 1024
Study 8435984 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 11
Study 8435984 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylureas
Number of subjects: 11
Study 3711377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tar oil applied twice daily with ultraviolet B phototherapy
Number of subjects: 22
Study 3711377 — intervention group
Group type: COMPARATOR
Intervention: Oil vehicle (an emollient) applied twice daily with ultraviolet B phototherapy
Number of subjects: 22
Study 3711377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tar oil in conjunction with ultraviolet B phototherapy
Number of subjects: 22
Study 30572580 — intervention group
Group type: EXPERIMENTAL
Intervention: D-allulose at doses of 0.1 g/kg·BW to 1.0 g/kg·BW
Number of subjects: 0
Study 30572580 — intervention group
Group type: EXPERIMENTAL
Intervention: D-allulose at 1.0 g/kg·BW
Number of subjects: 0
Study 29083443 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion and preventive care intervention (multi-topic personal reinforcement in small group sessions or preventive home visits)
Number of subjects: 2580
Study 29083443 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion and preventive care intervention
Number of subjects: 2580
Study 29083443 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2580
Study 25342738 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 26
Study 25342738 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 26